Table 2.
Outcome measures for subjects with at least 1 follow-up (N = 51)
| Placebo | Omega-3 | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable and | Initial Score | Final Score | Initial Score | Final Score | ||||
| Group | N | Mean (SD) | Mean (SD) | Slope | N | Mean (SD) | Mean (SD) | Slope |
| EPDS | ||||||||
| Pregnant | 9 | 15.78 (4.71) | 7.78 (4.15) | −1.07 (.61) | 12 | 17.50 (3.48) | 11.17 (6.78) | −1.10 (1.05) |
| Postpartum | 14 | 15.86 (2.93) | 8.29 (5.57) | −1.12 (.76) | 16 | 16.81 (4.02) | 10.81 (5.42) | −0.84 (.79) |
| EPDS Total | 23 | 15.83 (3.63) | 8.09 (4.96) | −1.10 (.69) | 28 | 17.11 (3.75) | 10.96 (5.92) | −0.95 (.90) |
| HAM-D | ||||||||
| Pregnant | 9 | 16.22 (1.20) | 10.22 (3.67) | −0.82 (.36) | 12 | 18.00 (3.16) | 14.17 (5.83) | −0.46 (.83) |
| Postpartum | 14 | 18.21 (2.36) | 9.71 (5.44) | −1.25 (1.04) | 16 | 19.50 (3.58) | 11.81 (5.17) | −1.14 (.53) |
| HAM-D Total | 23 | 17.43 (2.19) | 9.91 (4.74) | −1.08 (.86) | 28 | 18.86 (3.43) | 12.82 (5.48) | −0.85 (.75) |